Skip to main content Skip to navigation Skip to search

Enzymatica develops solutions that support the body's own defenses against virus, irritants and microorganisms.

the science that protects

articles & insights

Professor Glen Davison presented ColdZyme study at Global Health Summit

Enzymatica part of the Global Health Campaign

Abstract on clinical ColdZyme study published in British Journal of Sports Medicine

See all articles

press releases

September 9, 2024 - Regulatory press release

Enzymatica publishes supplementary prospectus

September 5, 2024 - Regulatory press release

Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

August 26, 2024 - Regulatory press release

Publication of prospectus regarding Enzymatica’s rights issue

August 16, 2024 - Regulatory press release

Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.

All press releases

financial reports

July 18, 2024

Interim report Q2/2024: Enzymatica builds momentum for expansion

April 25, 2024

Interim report Q1/2024: MDR certification opens up great commercial opportunities

April 9, 2024

Enzymatica publishes annual report for 2023

financial calendar

November 7, 2024

Interim report, Jan–Sep 2024

Download to calendar

February 18, 2025

Year-end report, Jan-Dec 2024

Download to calendar

enzyme science

Research has shown that in some cold-adapted marine organisms such as cod there is an enzyme with good protective properties.

research& development

Enzymatica focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme.

sustainability

Health and well-being constitute the foundation of our company, and we want to use resources wisely and sustainably.